Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on September 23, 2002

Hypertension. 2002
Published online before print September 23, 2002, doi: 10.1161/01.HYP.0000035396.27909.40
A more recent version of this article appeared on November 1, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/5/774    most recent
01.HYP.0000035396.27909.40v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kucharewicz, I.
Right arrow Articles by Buczko, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kucharewicz, I.
Right arrow Articles by Buczko, W.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Coagulation and fibronolysis

Submitted on February 21, 2002
Revised on April 8, 2002

Antithrombotic Effect of Captopril and Losartan Is Mediated by Angiotensin-(1-7)

Iwona Kucharewicz; Robert Pawlak; Tomasz Matys; Dariusz Pawlak; and Wlodzimierz Buczko*

From the Department of Pharmacodynamics, Medical Academy of Bialystok, Bialystok, Poland.

* To whom correspondence should be addressed. E-mail: pharmdyn{at}amb.edu.pl.

Abstract—It is well established that renin-angiotensin system blockers exert NO/prostacyclin-dependent antithrombotic effects. Because some beneficial effects of these drugs are mediated by angiotensin (Ang)-(1-7), in the present study we examined if their antithrombotic action could be mediated by Ang-(1-7). Intravenous infusion of Ang-(1-7) (1, 10, or 100 pmol/kg per minute for 2 hours) into rats developing venous thrombosis caused 50% to 70% reduction of the thrombus weight. This effect was dose-dependently reversed by cotreatment with A-779 (selective Ang-[1-7] receptor antagonist) or EXP 3174 (angiotensin type 1 receptor antagonist) but not by PD 123,319 (angiotensin type 2 receptor antagonist). Similarly, the antithrombotic effects of captopril (ACE inhibitor) and losartan (angiotensin type 1 receptor blocker) were attenuated by A-779 in a dose-dependent manner. The effect of Ang-(1-7) was completely abolished by concomitant administration of NO synthase inhibitor (NG-nitro-L-arginine methyl ester) and prostacyclin synthesis inhibitor (indomethacin), as has been shown previously for captopril and losartan. Thus, the antithrombotic effect of renin-angiotensin system blockers involves Ang-(1-7)-evoked release of NO and prostacyclin.


Key words: angiotensin • venous thrombosis • captopril • losartan • nitric oxide • prostacyclin • rats




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
L. D. Kluskens, S. A. Nelemans, R. Rink, L. de Vries, A. Meter-Arkema, Y. Wang, T. Walther, A. Kuipers, G. N. Moll, and M. Haas
Angiotensin-(1-7) with Thioether Bridge: An Angiotensin-Converting Enzyme-Resistant, Potent Angiotensin-(1-7) Analog
J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 849 - 854.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
A. Pignone, A. D. Rosso, K B. Brosnihan, F. Perfetto, R. Livi, G. Fiori, S. Guiducci, M. Cinelli, V. Rogai, A. Tempestini, et al.
Reduced circulating levels of angiotensin-(1 7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control
Ann Rheum Dis, October 1, 2007; 66(10): 1305 - 1310.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz
Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H666 - H672.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz
Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H684 - H691.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. M. Ferrario, A. J. Trask, and J. A. Jessup
Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. Langeveld, W. H. van Gilst, R. A. Tio, F. Zijlstra, and A. J.M. Roks
Angiotensin-(1-7) Attenuates Neointimal Formation After Stent Implantation in the Rat
Hypertension, January 1, 2005; 45(1): 138 - 141.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. H. Schmaier
The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R1 - R13.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. O. Sampaio, A. A. S. Nascimento, and R. A. S. Santos
Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats
Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1985 - H1994.
[Abstract] [Full Text] [PDF]